Korro Bio raised $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge based biotech will use the cash haul toward getting its preclinical program into the clinic, while also “establishing a…
Scholar Rock said Monday it raised $36 million in a Series B financing round led by Fidelity Management and Research Company. New investor Cormorant Asset Management also participated as well as existing investors Polaris Partners, Timothy Springer, ARCH Venture Partners,…
Gelesis, a Boston, MA-based clinical stage biotechnology company focused on the development of products to safely induce weight loss and improve glycemic control, closed a $31.5m growth financing round. Backers included Cormorant Asset Management, and current investors Invesco Asset Management,…
Axonics Modulation Technologies, Inc., an Irvine, CA-based developer of miniaturized implantable Sacral Neuromodulation technology, completed a $38.5m Series B financing. Backers included new investors Advent Life Sciences and Cormorant Asset Management, and existing investors Edmond de Rothschild Investment Partners, NeoMed…
